Roche (RHHBY) to Post Earnings on Thursday

Roche (OTCMKTS:RHHBY) will likely be releasing its resultson Thursday, July 23rd. Analysts expect the company to announce earnings of $1.58 per share and revenue of $38.1416 billion for the quarter.

Roche Trading Down 1.2%

RHHBY opened at $51.00 on Tuesday. Roche has a twelve month low of $37.51 and a twelve month high of $60.85. The firm’s 50-day simple moving average is $51.34 and its 200-day simple moving average is $52.68. The company has a quick ratio of 1.12, a current ratio of 1.38 and a debt-to-equity ratio of 0.72.

Analysts Set New Price Targets

A number of research firms have recently issued reports on RHHBY. Zacks Research cut shares of Roche from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Morgan Stanley upgraded Roche from an “underweight” rating to an “equal weight” rating and set a $46.00 price objective for the company in a research report on Friday, April 24th. Argus upgraded Roche from a “hold” rating to a “buy” rating in a report on Monday, April 6th. Finally, HSBC lowered shares of Roche from a “buy” rating to a “hold” rating in a report on Monday, July 6th. Four research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $51.50.

Institutional Trading of Roche

Several institutional investors and hedge funds have recently added to or reduced their stakes in RHHBY. Hancock Whitney Corp boosted its holdings in Roche by 4.8% during the third quarter. Hancock Whitney Corp now owns 24,488 shares of the company’s stock worth $1,024,000 after buying an additional 1,116 shares during the last quarter. Verity Asset Management Inc. raised its position in shares of Roche by 20.9% in the 3rd quarter. Verity Asset Management Inc. now owns 10,990 shares of the company’s stock valued at $459,000 after acquiring an additional 1,898 shares during the period. Atlas Capital Advisors Inc. acquired a new stake in shares of Roche in the 4th quarter valued at approximately $192,000. Finally, IHT Wealth Management LLC bought a new position in Roche during the 4th quarter worth approximately $400,000.

About Roche

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.